Eaton Vance Management’s Blueprint Medicines BPMC Stock Holding History

Eaton Vance Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3.39M	Sell	51,484 -126	-0.2%	-$8.09K	0.01%	886
2022 Q2	$2.61M	Sell	51,610 -54,219	-51%	-$3.18M	﹤0.01%	997
2022 Q1	$6.76M	Sell	105,829 -157,356	-60%	-$11.3M	0.01%	807
2021 Q4	$28.2M	Sell	263,185 -277	-0.1%	-$29K	0.03%	405
2021 Q3	$27.1M	Buy	263,462 +653	+0.2%	+$60.8K	0.04%	376
2021 Q2	$23.1M	Sell	262,809 -21,543	-8%	-$1.97M	0.03%	425
2021 Q1	$27.6M	Sell	284,352 -186,138	-40%	-$18.6M	0.04%	374
2020 Q4	$52.8M	Buy	470,490 +215,490	+85%	+$22.7M	0.08%	230
2020 Q3	$23.6M	Sell	255,000 -266,403	-51%	-$20.5M	0.04%	333
2020 Q2	$40.7M	Buy	521,403 +9,106	+2%	+$616K	0.08%	221
2020 Q1	$30M	Buy	512,297 +296,931	+138%	+$19.1M	0.07%	232
2019 Q4	$17.3M	Buy	215,366 +41,016	+24%	+$3.07M	0.03%	363
2019 Q3	$12.8M	Buy	174,350 +81,894	+89%	+$7.08M	0.03%	396
2019 Q2	$8.72M	Buy	+92,456	New	+$7.63M	0.02%	460

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Eaton Vance Management's BPMC Position: Q3 2022 in Review

Eaton Vance Management reduced its Blueprint Medicines (BPMC) stake by 0.24% in Q3 2022, selling an estimated $8.09K and leaving 51,484 shares worth $3.39M. The position accounts for 0.01% of the portfolio, ranked #886.

Eaton Vance Management first reported a position in BPMC in Q2 2019 and has held it in 14 quarters since. The position peaked at $52.8M in Q4 2020. 240 funds tracked by Wall St. Rank hold BPMC as of Q3 2022.

Eaton Vance Management held 51,484 shares of Blueprint Medicines worth $3.39M as of Q3 2022.
Eaton Vance Management sold 126 Blueprint Medicines shares in Q3 2022, an estimated $8.09K.
Blueprint Medicines made up 0.01% of Eaton Vance Management's portfolio in Q3 2022, its #886 holding.
Eaton Vance Management first reported a position in Blueprint Medicines in Q2 2019 and has held it in 14 quarters since.
Eaton Vance Management's Blueprint Medicines position peaked at $52.8M in Q4 2020.
240 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.